About: Bezlotoxumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections. This drug, along with actoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck Sharp & Dohme Corp for further development and commercialization. Actoxumab and bezlotoxumab are fully human monoclonal antibodies which bind C. difficile toxins A and B, respectively.

Property Value
dbo:abstract
  • بزلوتوكسوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج وللوقاية من عدوى كلوستريديوم ديفيسيلي آكتوكسوماب وبزلوتوكسوماب طورا في تجاربهما السريرية بالاشتراك بين مؤسسة ميداركس (Medarex Inc) ومدرسة الطب بجامعة ماساتشوستس. الأبحاث منح امتيازها فيما بعد لشركة للأدوية لغرض التطوير والتسويق. (ar)
  • Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections. This drug, along with actoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck Sharp & Dohme Corp for further development and commercialization. Actoxumab and bezlotoxumab are fully human monoclonal antibodies which bind C. difficile toxins A and B, respectively. A Phase III trial only showed a benefit from bezlotoxumab; the combination of actoxumab and bezlotoxumab worked no better to prevent recurrence of C. difficile associated diarrhea than bezlotoxumab alone. (en)
  • Le bezlotoxumab est un anticorps monoclonal dirigé contre la toxine B du clostridium difficile et utilisé comme médicament pour éviter la récidive des infections à ce germe. Le nom de spécialité donnée par Merck Sharp & Dohme Corp pour cette molécule est Zinplava.L'agence américaine des médicaments « FDA » a approuvé ZINPLAVA le 21 octobre 2016 pour prévenir les rechutes d'infection à Clostridium difficile.L'agence européenne du médicament a autorisé bezlotoxumab le 22 novembre 2016 (fr)
  • Безлотоксумаб — лекарственный препарат, моноклональное антитело для предотвращения повторной инфекции, вызванной Clostridium difficile. Одобрен для применения: США (2016). (ru)
dbo:alternativeName
  • Zinplava (en)
dbo:casNumber
  • 1246264-45-8
dbo:drugbank
  • DB13140
dbo:fdaUniiCode
  • 4H5YMK1H2E
dbo:kegg
  • D10453
dbo:medlinePlus
  • a617003
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 36383404 (xsd:integer)
dbo:wikiPageLength
  • 8945 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1092466783 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • J06 (en)
dbp:atcSuffix
  • BC03 (en)
dbp:c
  • 6464 (xsd:integer)
dbp:casNumber
  • 1246264 (xsd:integer)
dbp:chemspiderid
  • none (en)
dbp:dailymedid
  • Bezlotoxumab (en)
dbp:drugbank
  • DB13140 (en)
dbp:h
  • 9974 (xsd:integer)
dbp:kegg
  • D10453 (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUk
  • POM (en)
dbp:legalUs
  • Rx-only (en)
dbp:licenceEu
  • yes (en)
dbp:mabType
  • mab (en)
dbp:medlineplus
  • a617003 (en)
dbp:n
  • 1726 (xsd:integer)
dbp:o
  • 2014 (xsd:integer)
dbp:pregnancyAu
  • B2 (en)
dbp:routesOfAdministration
dbp:s
  • 46 (xsd:integer)
dbp:source
  • u (en)
dbp:target
  • Clostridium difficile toxin B (en)
dbp:tradename
  • Zinplava (en)
dbp:type
  • mab (en)
dbp:unii
  • 4 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • بزلوتوكسوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج وللوقاية من عدوى كلوستريديوم ديفيسيلي آكتوكسوماب وبزلوتوكسوماب طورا في تجاربهما السريرية بالاشتراك بين مؤسسة ميداركس (Medarex Inc) ومدرسة الطب بجامعة ماساتشوستس. الأبحاث منح امتيازها فيما بعد لشركة للأدوية لغرض التطوير والتسويق. (ar)
  • Le bezlotoxumab est un anticorps monoclonal dirigé contre la toxine B du clostridium difficile et utilisé comme médicament pour éviter la récidive des infections à ce germe. Le nom de spécialité donnée par Merck Sharp & Dohme Corp pour cette molécule est Zinplava.L'agence américaine des médicaments « FDA » a approuvé ZINPLAVA le 21 octobre 2016 pour prévenir les rechutes d'infection à Clostridium difficile.L'agence européenne du médicament a autorisé bezlotoxumab le 22 novembre 2016 (fr)
  • Безлотоксумаб — лекарственный препарат, моноклональное антитело для предотвращения повторной инфекции, вызванной Clostridium difficile. Одобрен для применения: США (2016). (ru)
  • Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections. This drug, along with actoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck Sharp & Dohme Corp for further development and commercialization. Actoxumab and bezlotoxumab are fully human monoclonal antibodies which bind C. difficile toxins A and B, respectively. (en)
rdfs:label
  • Bezlotoxumab (en)
  • بزلوتوكسوماب (ar)
  • Bezlotoxumab (fr)
  • Безлотоксумаб (ru)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License